PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25198668-14	2014	IL-18 -607AA and OPN -442TT genotypes can be used as positive predictive markers of interferon plus ribavirin treatment of HCV infection in the Pakistani population.	Ribavirin	100-109	interleukin 18	Homo sapiens	0-5	
16611188-0	2006	Modulation of the anti-inflammatory interleukin 10 and of proapoptotic IL-18 in patients with chronic hepatitis C treated with interferon alpha and ribavirin.	Ribavirin	148-157	interleukin 18	Homo sapiens	71-76	
24861285-4	2014	An association between IL-18 gene promoter polymorphisms and pegylated interferon (PEG-IFN) and ribavirin treatment outcomes has been reported for individuals with chronic hepatitis C virus genotype 1 (HCV-1).	Ribavirin	96-105	interleukin 18	Homo sapiens	23-28	
21398397-8	2011	CONCLUSION: Serum IL-10, IL-12, and IL-18 levels are predictive of the response to HCV treatment with pegylated interferon and ribavirin and are associated with amino acid substitutions in the ISDR and core region.	Ribavirin	127-136	interleukin 18	Homo sapiens	36-41	
16611188-10	2006	Treatment with interferon and ribavirin induced a significant decrease of IL-18 concentration independently of the viral response.	Ribavirin	30-39	interleukin 18	Homo sapiens	74-79	
15816475-0	2005	Up-regulation of IL-18 by interferon alpha-2b/ribavirin combination therapy induces an anti-viral effect in patients with chronic hepatitis C. BACKGROUND/AIMS: Recent large prospective trials demonstrated that the combination therapy of interferon (IFN)-alpha/ribavirin significantly increased a sustained virological response rate in patients with chronic hepatitis C. However, the potential mechanism of ribavirin is not clear.	Ribavirin	46-55	interleukin 18	Homo sapiens	17-22	
15816475-0	2005	Up-regulation of IL-18 by interferon alpha-2b/ribavirin combination therapy induces an anti-viral effect in patients with chronic hepatitis C. BACKGROUND/AIMS: Recent large prospective trials demonstrated that the combination therapy of interferon (IFN)-alpha/ribavirin significantly increased a sustained virological response rate in patients with chronic hepatitis C. However, the potential mechanism of ribavirin is not clear.	Ribavirin	260-269	interleukin 18	Homo sapiens	17-22	
15816475-0	2005	Up-regulation of IL-18 by interferon alpha-2b/ribavirin combination therapy induces an anti-viral effect in patients with chronic hepatitis C. BACKGROUND/AIMS: Recent large prospective trials demonstrated that the combination therapy of interferon (IFN)-alpha/ribavirin significantly increased a sustained virological response rate in patients with chronic hepatitis C. However, the potential mechanism of ribavirin is not clear.	Ribavirin	260-269	interleukin 18	Homo sapiens	17-22	
15816475-7	2005	CONCLUSIONS: This study suggests that ribavirin may contribute to the antiviral effect through up-regulation of IL-18 in combination with IFN in patients with chronic hepatitis C.	Ribavirin	38-47	interleukin 18	Homo sapiens	112-117